# EDGAR Filing Document

**Accession Number:** 0001506983
**File Stem:** 0001493152-25-012735
**Filing Date:** 2025-9
**Character Count:** 58450
**Document Hash:** eddea8b41c5e75c21b2ce74f41438657
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-012735.hdr.sgml**: 20250905

**ACCESSION NUMBER**: 0001493152-25-012735

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 17

**FILED AS OF DATE**: 20250905

**DATE AS OF CHANGE**: 20250905

**EFFECTIVENESS DATE**: 20250905

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Glucotrack, Inc.
- **CENTRAL INDEX KEY:** 0001506983
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 980668934
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-290076
- **FILM NUMBER:** 251297025

**BUSINESS ADDRESS:**
- **STREET 1:** 301 RT 17 NORTH
- **STREET 2:** SUITE 800
- **CITY:** RUTHERFORD
- **STATE:** NJ
- **ZIP:** 07070
- **BUSINESS PHONE:** 972 (8) 675-7878

**MAIL ADDRESS:**
- **STREET 1:** 301 RT 17 NORTH
- **STREET 2:** SUITE 800
- **CITY:** RUTHERFORD
- **STATE:** NJ
- **ZIP:** 07070

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GlucoTrack, Inc.
- **DATE OF NAME CHANGE:** 20220328

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Integrity Applications, Inc.
- **DATE OF NAME CHANGE:** 20101203

**As filed with the Securities and Exchange Commission on September 5, 2025**

**Registration No. 333-**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM S-8**

**REGISTRATION STATEMENT**

***UNDER***

***THE SECURITIES ACT OF 1933***

**GLUCOTRACK, INC.**

**(Exact Name of Registrant as Specified in Its Charter)**

---

| | |
|:---|:---|
| **Delaware** | **98-0668934** |
| **(State or Other Jurisdiction of**<br> **Incorporation or Organization)** | **(I.R.S. Employer**<br> **Identification Number)** |
| **301 Rte. 17 North, Ste. 800**<br> **Rutherford, NJ** | <br> **07070** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**Glucotrack, Inc. 2024 Equity Incentive Plan**

**(Full Title of the Plan)**

**Paul Goode**

**Chief Executive Officer**

**Glucotrack, Inc.**

**301 Rte. 17 North, Ste. 800, Rutherford, NJ 07070**

**(Name and Address of Agent for Service)**

**(201) 842-7715**

**(Telephone Number, Including Area Code, of Agent for Service)**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**PART I**

**REGISTRATION OF ADDITIONAL SHARES PURSUANT TO GENERAL INSTRUCTION E**

Pursuant to General Instruction E of Form S-8, Glucotrack, Inc. (the "Registrant") is filing this Registration Statement on Form S-8 (this "Registration Statement") with the U.S. Securities and Exchange Commission (the "Commission") to register 124,555 additional shares of the Registrant's common stock for issuance under the Glucotrack, Inc. 2024 Equity Incentive Plan (the "Plan"), pursuant to an amendment of the Plan increasing the maximum aggregate number of shares that may be issued under the Plan to 125,000, effective as of May 22, 2025 (as reduced in connection with the Registrant's one-for-sixty (1:60) reverse stock split, effective June 13, 2025). This Registration Statement hereby incorporates by reference the contents of the Registrant's registration statement on Form S-8 filed with the Commission on August 19, 2024 (File No. 333-281627), which registered 535,127 shares (which was subsequently reduced to 26,757 shares, in connection with the Registrant's one-for-twenty (1:20) reverse stock split, effective February 3, 2025, and further reduced to 445 shares in connection with the Registrant's one-for-sixty (1:60) reverse stock split, effective June 13, 2025). In accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of Form S-8 has been omitted from this Registration Statement pursuant to Rule 428(b)(1) of the Securities Act of 1933, as amended (the "Securities Act").

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3.** **Incorporation of Documents by Reference.** 

The following documents filed with the Commission are incorporated herein by reference:

● The Registrant's Annual Report on [Form 10-K](https://www.sec.gov/Archives/edgar/data/1506983/000164117225001861/form10-k.htm) for the fiscal year ended December 31, 2024 filed with the SEC on March 31, 2025;

● The Registrant's Quarterly Reports on Form 10-Q for the quarters ended [March 31, 2025](https://www.sec.gov/Archives/edgar/data/1506983/000164117225010384/form10-q.htm) and [June 30, 2025](https://www.sec.gov/Archives/edgar/data/1506983/000149315225011981/form10-q.htm) filed with the SEC on May 14, 2025 and August 14, 2025, respectively;

● The Registrant's Current Reports on Form 8-K filed with the SEC on [January 7, 2025](https://www.sec.gov/Archives/edgar/data/1506983/000149315225001222/form8-k.htm) , [January 13, 2025](https://www.sec.gov/Archives/edgar/data/1506983/000149315225001982/form8-k.htm) , (as amended on [January 14, 2025](https://www.sec.gov/Archives/edgar/data/1506983/000149315225002027/form8-ka.htm)), [January 29, 2025](https://www.sec.gov/Archives/edgar/data/1506983/000149315225004104/form8-k.htm) , [February 4, 2025](https://www.sec.gov/Archives/edgar/data/1506983/000149315225004793/form8-k.htm) , [February 5, 2025](https://www.sec.gov/Archives/edgar/data/1506983/000149315225004953/form8-k.htm) , [March 13, 2025](https://www.sec.gov/Archives/edgar/data/1506983/000149315225010189/form8-k.htm) , [March 31, 2025](https://www.sec.gov/Archives/edgar/data/1506983/000164117225001831/form8-k.htm) , [April 4, 2025](https://www.sec.gov/Archives/edgar/data/1506983/000164117225002802/form8-k.htm) , [May 14, 2025](https://www.sec.gov/Archives/edgar/data/1506983/000164117225010377/form8-k.htm) , [May 23, 2025](https://www.sec.gov/Archives/edgar/data/1506983/000164117225012287/form8-k.htm) , [June 16, 2025](https://www.sec.gov/Archives/edgar/data/1506983/000164117225015194/form8-k.htm) , and [July 24, 2025](https://www.sec.gov/Archives/edgar/data/1506983/000149315225011386/form8-k.htm) (as amended on [July 25, 2025](https://www.sec.gov/Archives/edgar/data/1506983/000149315225011423/form8-ka.htm)); and

● The description of the Registrant's common stock contained in its Registration Statement on [Form 8-A](https://www.sec.gov/Archives/edgar/data/1506983/000149315221030843/form8-a12b.htm) , as filed with the SEC on December 8, 2021, including any amendments or reports filed with the SEC for the purpose of updating such description.

All documents subsequently filed with the SEC by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, prior to the filing of a post-effective amendment to this registration statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this registration statement (in each case excluding any information furnished and not filed according to applicable rules, such as information furnished pursuant to Item 2.02 or Item 7.01 on any Current Report on Form 8-K) and to be part hereof from the date of filing of such documents.

Any statement contained in a document incorporated or deemed to be incorporated by reference in this registration statement shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement contained in this registration statement, or in any other subsequently filed document that also is or is deemed to be incorporated by reference in this registration statement, modifies or supersedes such prior statement. Any statement contained in this registration statement shall be deemed to be modified or superseded to the extent that a statement contained in a subsequently filed document that is or is deemed to be incorporated by reference in this registration statement modifies or supersedes such prior statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

**Item 5.** **Interests of Named Experts and Counsel.** 

None.

**Item 8.** **Exhibits.** 

The following exhibits are filed as part of this Registration Statement:

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 4.1 | [Certificate of Incorporation of Integrity Applications, Inc. (incorporated herein by reference to Exhibit 3.1 to our Registration Statement on Form S-1 filed with the SEC on August 22, 2011)](https://www.sec.gov/Archives/edgar/data/1506983/000114420411048873/v232648_ex3-1.htm) |
| 4.2 | [Certificate of Amendment to Certificate of Incorporation of Integrity Applications, Inc. (incorporated herein by reference to Exhibit 3.2 to our Registration Statement on Form S-1 filed with the SEC on August 22, 2011)](https://www.sec.gov/Archives/edgar/data/1506983/000114420411048873/v232648_ex3-2.htm) |
| 4.3 | [Bylaws of Integrity Applications, Inc. (incorporated herein by reference to Exhibit 3.3 to our Registration Statement on Form S-1 filed with the SEC on August 22, 2011)](https://www.sec.gov/Archives/edgar/data/1506983/000114420411048873/v232648_ex3-3.htm) |
| 4.4 | [Certificate of Amendment to Certificate of Incorporation of Integrity Applications, Inc. (incorporated herein by reference to Exhibit 99.1 to our Current Report on Form 8-K filed with the SEC on April 23, 2020)](https://www.sec.gov/Archives/edgar/data/1506983/000149315220006997/ex99-1.htm) |
| 4.5 | [Amendments to The Company's Certificate of Incorporation (incorporated herein by reference to Exhibit 3.7 to our Annual Report on Form 10-K, filed with the SEC on March 31, 2022)](https://www.sec.gov/Archives/edgar/data/1506983/000149315222008417/ex3-7.htm) |
| 4.6 | [First Amendment to Bylaws dated June 14, 2024 (incorporated herein by reference to Exhibit 3.01 to our Current Report on Form 8-K filed on June 20, 2024)](https://www.sec.gov/Archives/edgar/data/1506983/000149315224024427/ex3-01.htm) |
| 4.7 | [Certificate of Amendment to Amended and Restated Certificate of Incorporation, as filed with the Secretary of State of the State of Delaware on May 17, 2024 (incorporated herein by reference to Exhibit 3.1 to our Current Report on Form 8-K filed on May 20, 2024)](https://www.sec.gov/Archives/edgar/data/1506983/000149315224020548/ex3-1.htm) |
| 4.8 | [Certificate of Amendment of Certificate of Incorporation of Glucotrack, Inc., dated January 3, 2025 (incorporated herein by reference to Exhibit 3.1 to our Current Report on Form 8-K filed on January 7, 2025)](https://www.sec.gov/Archives/edgar/data/1506983/000149315225001222/ex3-1.htm) |
| 4.9 | [Certificate of Amendment to Certificate of Incorporation, as filed with the Secretary of State of the State of Delaware on February 3, 2025 (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed by Glucotrack, Inc. on February 4, 2025)](https://www.sec.gov/Archives/edgar/data/1506983/000149315225004793/ex3-1.htm) |
| 4.10 | [Certificate of Amendment to Certificate of Incorporation, as filed with the Secretary of State of the State of Delaware on June 13, 2025 (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed by Glucotrack, Inc. on June 16, 2025)](https://www.sec.gov/Archives/edgar/data/1506983/000164117225015194/ex3-1.htm) |
| 5.1\* | [Opinion of Nelson Mullins Riley & Scarborough LLP as to the legality of the securities being registered that constitute original issue shares.](ex5-1.htm) |
| 23.1\* | [Consent of Fahn Kanne & Co., an Independent Public Accounting Firm.](ex23-1.htm) |
| 23.2\* | [Consent of Nelson Mullins Riley & Scarborough LLP (included as part of Exhibit 5.1).](ex5-1.htm) |
| 24.1\* | [Power of Attorney (included on signature page).](#a_001) |
| 99.1 | [Glucotrack, Inc. 2024 Equity Incentive Plan (incorporated herein by reference to Appendix A to our DEF 14A filed with the Commission on April 1, 2024)](https://www.sec.gov/Archives/edgar/data/1506983/000149315224012324/formdef14a.htm)<br>|
| 99.2 | [Amendment to the Glucotrack, Inc. 2024 Equity Incentive Plan (incorporated herein by reference to Exhibit 99.1 to our current report on Form 8-K filed on May 23, 2025)](https://www.sec.gov/Archives/edgar/data/1506983/000164117225012287/ex99-1.htm) |
| 99.3\* | [Form of Option Award Agreement](ex99-3.htm) |
| 107\* | [Filing Fee Table](ex107.htm) |

---

\* Filed herewith.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Rutherford, State of New Jersey, on September 5, 2025.

---

| | |
|:---|:---|
| GLUCOTRACK, INC. | GLUCOTRACK, INC. |
| By: | */s/ Paul Goode* |
|  | Paul Goode |
|  | Chief Executive Officer |

---

**POWER OF ATTORNEY**

We, the undersigned officers and directors of Glucotrack, Inc., hereby, severally constitute and appoint Paul Goode as our true and lawful attorney-in-fact and agent, with full power of substitution and re-substitution, in any and all capacities, to sign this Registration Statement on Form S-8 and any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto such attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as she/he might or could do in person, hereby ratifying and confirming all that such attorney-in-fact and agent, or her/his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| */s/ Paul Goode* | Chief Executive Officer and Director | September 5, 2025 |
| Paul Goode | (*Principal Executive Officer)* |  |
| */s/ Peter Wulff* | Chief Financial Officer | September 5, 2025 |
| Peter Wulff | *(Principal Financial and Accounting Officer)* |  |
| */s/ Erin Carter* | Director | September 5, 2025 |
| Erin Carter |  |  |
| */s/ Luis Malave* | Director | September 5, 2025 |
| Luis Malave |  |  |
| */s/ Andrew Balo* | Director | September 5, 2025 |
| Andrew Balo |  |  |
| */s/ Victoria Carr-Brendel* | Director | September 5, 2025 |
| Victoria Carr-Brendel |  |  |

---

## Exhibit 5.1

**Exhibit 5.1**

---

| | |
|:---|:---|
| ![](ex5-1_001.jpg) | **NELSON MULLINS RILEY & SCARBOROUGH LLP**<br> **ATTORNEYS AND COUNSELORS AT LAW** |
|  | **301 Hillsborough Street**<br> **Suite 1400**<br> **Raleigh, NC 27603**<br> **T: 919.329.3804** <br> **nelsonmullins.com** |

---

September 5, 2025

Glucotrack, Inc.

301 Rte. 17 North, Ste. 800

Rutherford, NJ 07070

RE: Registration Statement on Form S-8 in connection with the Glucotrack, Inc. 2024 Equity Incentive Plan, as amended.

Ladies and Gentlemen:

We have acted as counsel to Glucotrack, Inc., a Delaware corporation (the "<u>Company</u>"), in connection with the Registration Statement on Form S-8 (the "<u>Registration Statement</u>") to be filed by the Company on or about September 5, 2025 with the U.S. Securities and Exchange Commission (the "<u>SEC</u>") under the Securities Act of 1933, as amended, related to the offering of up to an aggregate of 124,550 shares of the Company's common stock, par value $0.001 per share (the "<u>Shares</u>"), issuable under the Glucotrack, Inc. 2024 Equity Incentive Plan (as amended, the "<u>Plan</u>"). This opinion letter is furnished pursuant to the requirement of Item 601(b)(5) of Regulation S-K promulgated by the SEC.

In reaching the opinions set forth herein, we have examined and are familiar with originals or copies, certified or otherwise identified to our satisfaction, of such documents and records of the Company and such statutes, regulations and other instruments, certificates and records as we deem necessary or advisable for the purposes of this opinion letter, including, without limitation, the Plan, the Company's Certificate of Incorporation, as amended, the Company's Bylaws, as amended, and certain resolutions adopted by the Company's board of directors.

As to any facts material to our opinions, we have made no independent investigation or verification of such facts and have relied, to the extent that we deem such reliance proper, on certificates and oral or written statements and other information of or from officers and representatives of the Company and public officials and on factual information included in the Company's filings with the SEC. We have assumed the completeness and authenticity of all documents submitted to us as originals, the completeness and conformity to the originals of all documents submitted to us as copies thereof, the genuineness of all signatures, the legal capacity and mental competence of natural persons, and that all information contained in all documents reviewed by us is true, correct and complete. In addition, we have assumed that the Shares will be issued in accordance with the Plan, as applicable, and that the Company will receive legal consideration for the issuance of the Shares (in an amount not less than the par value thereof).

**California \| Colorado \| District of Columbia \| Florida \| Georgia \| Illinois \| Maryland \| Massachusetts \| Minnesota**

**New York \| North Carolina \| Ohio \| Pennsylvania \| South Carolina \| Tennessee \| Texas \| Virginia \| West Virginia**

Glucotrack, Inc.

September 5, 2025

On the basis of the foregoing, and subject to the foregoing qualifications, assumptions and limitations and the further limitations set forth below, we are of the opinion that the Shares that may be issued and sold from time to time in accordance with the Plan have been duly authorized and, when issued and delivered in accordance with the Plan, the Shares will be validly issued, fully paid and nonassessable.

This opinion letter is rendered as of the date hereof, and we assume no obligations to advise you of changes in law or fact (or the effect thereof on the opinions expressed herein) that hereafter may come to our attention. We hereby consent to the filing of this opinion letter with the SEC as Exhibit 5.1 to the Registration Statement. In giving this consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended, or the rules and regulations of the SEC.

Our opinions are based upon and limited to the Delaware General Corporation Law, and no opinion is expressed as to the laws of any other jurisdiction. We do not find it necessary for the purposes of this opinion, and accordingly we do not purport to cover herein, the application of the securities or "Blue Sky" laws of the various states to the issuance and sale of any of the Shares.

---

| |
|:---|
| Sincerely, |
| /s/ Nelson Mullins Riley & Scarborough LLP |
| Nelson Mullins Riley & Scarborough LLP |

---

## Exhibit 23.1

**Exhibit 23.1**

![](ex23-1_001.jpg)

**Fahn Kanne & Co.**<br> Head Office<br> 32 Hamasger Street<br> Tel-Aviv 6721118, ISRAEL<br> PO Box 36172, 6136101<br>T +972 3 7106666<br> F +972 3 7106660<br> www.gtfk.co.il<br>

**CONSENT OF INDEPENDENT<br> REGISTERED PUBLIC ACCOUNTING FIRM**

We have issued our report dated March 31, 2025, with respect to the consolidated financial statements of Glucotrack Inc., included in the Annual Report on Form 10-K for the year ended December 31, 2024, which is incorporated by reference in this Registration Statement. We consent to the incorporation by reference of the aforementioned report in the Registration Statement.

**FAHN KANNE & CO. GRANT THORNTON ISRAEL**

/s/ Fahn Kanne & Co. Grant Thornton Israel

Tel-Aviv, Israel

September 5, 2025

**Certified Public Accountants**

Fahn Kanne & Co. is the Israeli member firm of Grant Thornton International Ltd.

## Exhibit 99.3

**Exhibit 99.3**

**GLUCOTRACK INC.**

**2024 EQUITY INCENTIVE PLAN**

**<u>STOCK OPTION GRANT NOTICE</u>**

Glucotrack Inc., a Delaware corporation (the "***Company***"), pursuant to the Glucotrack Inc. 2024 Equity Incentive Plan as it may be amended from time to time (the "***Plan***"), hereby grants to the Optionholder (as defined below) an option to purchase the number of shares of common stock, par value $0.001 per share of the Company ("***Common Stock***") set forth below (this "***Option***"). This Option is subject to all of the terms and conditions as set forth in this Stock Option Grant Notice (this "***Grant Notice***"), in the corresponding Stock Option Agreement (the "***Option Agreement***"), the Plan, and the Notice of Exercise, all of which are attached hereto and incorporated herein in their entirety. Capitalized terms not explicitly defined herein but defined in the Plan or the corresponding Option Agreement will have the same definitions as in the Plan or the corresponding Option Agreement. If there is any conflict between the terms in this Grant Notice, **<u>Exhibit A</u>** to this Grant Notice, the corresponding Option Agreement, the Plan and the Notice of Exercise, then such conflict or inconsistency shall be resolved by giving such documents precedence in the following order: **<u>Exhibit A</u>**, this Grant Notice, the corresponding Option Agreement, the Plan and then the Notice of Exercise.

---

| | |
|:---|:---|
| Optionholder: | [Name] (the "***Optionholder***") |
| Date of Grant: | __________ _____, 20__ (the "***Date of Grant***") |
| Vesting Commencement Date: | __________ _____, 20__ (the "***Vesting Commencement Date***") |
| Common Stock Subject to this Option: | __________ (_____) |
| Exercise Price (Per share of Common Stock): | $__.__ |
| Total Exercise Price: | $__________ |
| Type of Grant (check one): | ☐ Incentive Stock Option |
|  | ☐ Non-Qualified Stock Option |
| Expiration Date: | ☐ Tenth (10<sup>th</sup>) Anniversary of the Date of Grant |
|  | ☐ Fifth (5<sup>th</sup>) Anniversary of the Date of Grant (for ten percent (10%) shareholders if this Option is an Incentive Stock Option) |
| Vesting Schedule: | This Award shall vest pursuant to the schedule set forth in **<u>Exhibit A</u>**, which is attached hereto and incorporated herein in its entirety. |
| Payment: | By one or a combination of the following items (described in the corresponding Option Agreement): |
|  | By cash, check, bank draft or money order payable to the Company |
|  | Pursuant to a Regulation T Program if the shares are publicly traded |
|  | By delivery of already-owned shares if the shares are publicly traded |
|  | Subject to the Administrator's consent, to be made in its sole discretion, at the time of exercise, by a "net exercise" arrangement. |

---

**Additional Terms/Acknowledgements:**

The Optionholder acknowledges receipt of, and understands and agrees to, this Grant Notice, the corresponding Option Agreement, the Plan and the Notice of Exercise. The Optionholder acknowledges and agrees that this Grant Notice, the corresponding Option Agreement and the Notice of Exercise may not be modified, amended or revised except as provided in the Plan. The Optionholder further acknowledges that as of the Date of Grant, this Grant Notice, the corresponding Option Agreement, the Plan and the Notice of Exercise set forth the entire understanding between the Optionholder and the Company regarding this Option and supersede all prior oral and written agreements, promises and/or representations on that subject.

As a pre-condition to exercise, the Optionholder (or beneficiary, as the case may be) shall be required to execute a stock restriction agreement presented by the Company at the time of exercise, along with any other agreement among the Company and its stockholders that the Company requires be executed by the Optionholder, including an agreement which provides that the Optionholder may not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale, with respect to the Common Stock or other securities of the Company held by the Optionholder during the one hundred and eighty (180) day period following the effective date of a registration statement of the Company filed under the Securities Act of 1933, as amended, or such other applicable period as the underwriters or the Company shall reasonably request consistent with other shares issued in accordance with the Plan. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to any such restricted securities until the end of such period.

By accepting this Option, you consent to receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.

*Signatures on Following Page*

 

---

| | |
|:---|:---|
| **GLUCOTRACK INC.** | **OPTIONHOLDER** |
| By: |  |
|  | Signature |
| Title: |  |
| Date: |  |

---

Attachments: Option Agreement, Glucotrack Inc. 2024 Equity Incentive Plan, Notice of Exercise

**GLUCOTRACK INC.**

**2024 EQUITY INCENTIVE PLAN**

**<u>STOCK OPTION GRANT NOTICE</u>**

**EXHIBIT A**

**VESTING SCHEDULE**

[Insert applicable vesting schedule]; <u>provided, that</u> the Optionholder remains actively providing services to the Company or any of its Affiliates as of each such date.

Upon the Optionholder's termination of employment or other service with the Company and its Affiliates for any or no reason, any unvested portion of this Option as of the date of such termination shall be forfeited.

**GLUCOTRACK INC.**

**2024 EQUITY INCENTIVE PLAN**

**<u>STOCK OPTION GRANT NOTICE</u>**

**ATTACHMENT I**

**OPTION AGREEMENT**

**GLUCOTRACK INC.**

**2024 EQUITY INCENTIVE PLAN**

**<u>STOCK OPTION AGREEMENT</u>**

**<u>(INCENTIVE STOCK OPTION OR NON-QUALIFIED STOCK OPTION)</u>**

Pursuant to your Stock Option Grant Notice (the "***Grant Notice***") and this Stock Option Agreement (this "***Agreement***"), Glucotrack Inc., a Delaware corporation (the "***Company***") has granted you an option under the Glucotrack Inc. 2024 Equity Incentive Plan (the "***Plan***") to purchase the number of shares of Common Stock indicated in the Grant Notice at the exercise price indicated in the Grant Notice (this "***Option***"). This Option is granted to you effective as of the date of grant set forth in the Grant Notice (the "***Date of Grant***"). If there is any conflict between the terms in the Grant Notice, **<u>Exhibit A</u>** to the Grant Notice, this Agreement, the Plan and the Notice of Exercise, then such conflict shall be resolved by giving such documents precedence in the following order: **<u>Exhibit A</u>**, the Grant Notice, this Agreement, the Plan and then the Notice of Exercise. Capitalized terms not explicitly defined in this Agreement or in the Grant Notice but defined in the Plan will have the same definitions as in the Plan.

The details of this Option, in addition to those set forth in the Grant Notice and the Plan, are as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1. <u>Vesting; No Shareholder Rights</u>.** This Option will vest as provided in your Grant Notice. vesting will cease upon the termination of your employment or service with the Company and its Affiliates, except as may be provided otherwise in the Vesting Schedule in **<u>Exhibit A</u>** to your Grant Notice. You will not be deemed to be the holder of, or have any of the rights of, a stockholder with respect to this Option unless and until this Option vests and you exercise this Option in accordance with this Agreement and the Company has issued and delivered Common Stock to you and your name shall have been entered as a stockholder of record on the books of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2. <u>Number of Shares and Exercise Price</u>.** The number of shares of Common Stock subject to this Option and your Exercise Price per share are set forth in your Grant Notice and will be adjusted in the event of changes in capital structure and similar events as provided in Section 14 of the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3. <u>Exercise Restriction for Non-Exempt Employees</u>.** If you are an employee eligible for overtime compensation under the Fair Labor Standards Act of 1938, as amended (that is, a "***Non-Exempt Employee***"), and except as provided below, you may not exercise this Option until you have completed at least six (6) months of service measured from the Date of Grant, even if you have already been an employee of the Company or its Affiliates for more than six (6) months. Consistent with the provisions of the Worker Economic Opportunity Act, you may exercise this Option as to any vested portion prior to such six (6) month anniversary in the case of (i) your death or disability, (ii) a Change in Control or (iii) your termination of your employment or service on your "retirement" (as defined in the Company's benefit plans).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. **<u>Method of Payment</u>.** You must pay the full amount of the Exercise Price for the Common Stock you wish to exercise. You may pay the Exercise Price in cash or by check, bank draft or money order payable to the Company or in any other manner permitted by your Grant Notice, which may include one or more of the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Provided that at the time of exercise the Common Stock is publicly traded, pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of Common Stock, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds. This manner of payment is also known as a "cashless exercise", "broker-assisted exercise", "same day sale", or "sell to cover".

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Provided that at the time of exercise the Common Stock is publicly traded, by delivery to the Company (either by actual delivery or attestation) of already-owned Common Stock that is owned free and clear of any liens, claims, encumbrances or security interests, and that are valued at Fair Market Value on the date of exercise. "***Delivery***" for these purposes, in the sole discretion of the Company at the time you exercise this Option, will include delivery to the Company of your attestation of ownership of such Common Stock in a form approved by the Company. You may not exercise this Option by delivery to the Company of Common Stock if doing so would violate the provisions of any Applicable Law, regulation or agreement restricting the redemption of the Company's stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Subject to the consent of the Company at the time of exercise, by a "net exercise" arrangement pursuant to which the Company will reduce the number of shares of Common Stock issued upon exercise of this Option by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price. You must pay any remaining balance of the aggregate exercise price not satisfied by the "net exercise" in cash or other permitted form of payment. Common Stock will no longer be outstanding under this Option and will not be exercisable thereafter if those shares (i) are used to pay the exercise price pursuant to the "net exercise," (ii) are delivered to you as a result of such exercise, and (iii) are withheld to satisfy your tax withholding obligations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5. <u>Whole Shares</u>.** You may exercise this Option only for whole shares of Common Stock unless pursuant to the terms of your Grant Notice you were granted an option to purchase fractional shares of Common Stock or your vesting schedule provides for vesting in fractional shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6. <u>Securities and Other Law Compliance</u>.** In no event may you exercise this Option unless the Common Stock issuable upon exercise are then registered under the Securities Act or, if not registered, the Company has determined that your exercise and the issuance of the shares would be exempt from the registration requirements of the Securities Act. The exercise of this Option also must comply with all other Applicable Laws and regulations governing this Option (including pursuant to an International Addendum, if applicable), and you may not exercise this Option if the Company determines that such exercise would not be in material compliance with such laws and regulations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**7. <u>Term</u>.** You may not exercise this Option before the Date of Grant or after the expiration of this Option's term. Except as may be provided otherwise in the Vesting Schedule in **<u>Exhibit A</u>** to your Grant Notice or in an employment or other agreement between you and the Company, the term of this Option expires (subject to the provisions of Section 7(c) of the Plan in the event that this Option is an Incentive Stock Option and you, on the Date of Grant, own shares representing more than ten percent (10%) of the combined voting power of the Company) upon the earliest of the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) immediately upon the termination of your service with the Company or an Affiliate for Cause;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) ninety (90) days after the termination of your service with the Company or an Affiliate for any reason other than Cause, your Disability (as defined below) or your death (except as otherwise provided in <u>Section 7(d)</u> below); provided, however, that if during any part of such ninety (90) day period this Option is not exercisable solely because of the condition set forth in the section above relating to "Securities Law Compliance," this Option will not expire until the earlier of the Expiration Date or until it has been exercisable for an aggregate period of ninety (90) days after the termination of your service with the Company or an Affiliate; provided further, that if (i) you are a Non-Exempt Employee, (ii) your service with the Company or an Affiliate terminates within six (6) months after the Date of Grant, and (iii) you have vested in a portion of this Option at the time of your termination of your service with the Company or an Affiliate, this Option will not expire until the earlier of (x) the later of (A) the date that is one hundred and twenty (120) days after the Date of Grant, and (B) the date that is ninety (90) days after the termination of your service with the Company or an Affiliate, and (y) the Expiration Date;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) one (1) year after the termination of your service with the Company or an Affiliate due to your Disability (except as otherwise provided in <u>Section 7(d)</u>) below. For purposes of this Agreement, "***Disability***" means your inability to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or that has lasted or can be expected to last for a continuous period of not less than twelve (12) months as provided in Sections 22(e)(3) and 409A(a)(2)(c)(i) of the Code, and will be determined by the Administrator on the basis of such medical evidence as the Administrator deems warranted under the circumstances;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) one (1) year after your death if you die either during your service with the Company or within ninety (90) days after your service with the Company terminates for any reason other than Cause;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) the Expiration Date indicated in your Grant Notice; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) the day before the tenth (10<sup>th</sup>) anniversary of the Date of Grant.

If this Option is an Incentive Stock Option, note that to obtain the federal income tax advantages associated with an Incentive Stock Option, the Code requires that at all times beginning on the Date of Grant and ending on the day three (3) months before the date of this Option's exercise, you must be an employee of the Company or an Affiliate, except in the event of your death or Disability. The Company has provided for extended exercisability of this Option under certain circumstances for your benefit but cannot guarantee that this Option will necessarily be treated as an Incentive Stock Option if you continue to provide services to the Company or an Affiliate as a consultant or director after your employment terminates or if you otherwise exercise this Option more than three (3) months after the date your employment with the Company or an Affiliate terminates.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8. <u>Exercise</u>.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) You may exercise the vested portion of this Option during its term by (i) delivering a Notice of Exercise (in a form designated by the Company) and completing such other documents and/or procedures designated by the Company for exercise and (ii) paying the Exercise Price and any applicable withholding taxes to the Company's Secretary, stock plan administrator, or such other person as the Company may designate, together with such additional documents as the Company may then require.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) By exercising this Option you agree that, as a condition to any exercise of this Option, the Company may require you and you hereby agree to enter into an arrangement providing for the payment by you to the Company of any tax withholding obligation of the Company arising by reason of (i) the exercise of this Option, or (ii) the disposition of Common Stock acquired upon such exercise.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) If this Option is an Incentive Stock Option, by exercising this Option you agree that you will notify the Company in writing within fifteen (15) days after the date of any disposition of any of the shares of the Common Stock issued upon exercise of this Option that occurs within two (2) years after the Date of Grant or within one (1) year after such shares of Common Stock are transferred upon exercise of this Option.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**9. <u>Transferability</u>.** Except as otherwise provided in this <u>Section 9</u>, this Option is not assignable or transferable, except by will or by the laws of descent and distribution and is exercisable during your life only by you. Without limiting the generality of the foregoing, this Option may not be sold, assigned, transferred or otherwise disposed of, or pledged or hypothecated in any manner (whether by operation of law or otherwise), and shall not be subject to execution, attachment or other process. Any assignment, transfer, sale, pledge, hypothecation or other disposition of this Option or any attempt to make any such levy of execution, attachment or other process will cause this Option to terminate immediately, unless the Administrator, in his sole discretion, specifically waives applicability of this provision.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) *Certain Trusts*. Upon receiving written permission from the Administrator, you may transfer this Option to a trust if you are considered to be the sole beneficial owner (determined under Section 671 of the Code and applicable state law) while this Option is held in the trust. You and the trustee must enter into transfer and other agreements required by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) *Domestic Relations Orders*. Upon receiving written permission from the Administrator, and provided that you and the designated transferee enter into transfer and other agreements required by the Company, you may transfer this Option pursuant to the terms of a domestic relations order, official marital settlement agreement or other divorce or separation instrument as permitted by Treasury Regulation 1.421-1(b)(2) that contains the information required by the Company to effectuate the transfer. You are encouraged to discuss the proposed terms of any division of this Option with the Company prior to finalizing the domestic relations order or marital settlement agreement to help ensure the required information is contained within the domestic relations order or marital settlement agreement. If this Option is an Incentive Stock Option, this Option may be deemed to be a Non-Qualified Stock Option as a result of such transfer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) *Beneficiary Designation*. Upon receiving written permission from the Administrator, you may, by delivering written notice to the Company, in a form approved by the Company and any broker designated by the Company to handle option exercises, designate a third party who, on your death, will thereafter be entitled to exercise this Option and receive the Common Stock or other consideration resulting from such exercise. In the absence of such a designation, your executor or administrator of your estate will be entitled to exercise this Option and receive, on behalf of your estate, the Common Stock or other consideration resulting from such exercise.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**10. <u>Option not a Service Contract</u>.** This Option is not an employment or service contract, and nothing in this Option will be deemed to create in any way whatsoever any obligation on your part to continue in the employ or service of the Company or an Affiliate, or of the Company or an Affiliate to continue your employment or service. In addition, nothing in this Option will obligate the Company or an Affiliate, their respective stockholders, boards of directors, officers or employees to continue any relationship that you might have as a member of the Company's Board or a consultant for the Company or an Affiliate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**11. <u>Withholding Obligations</u>.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) At the time you exercise this Option, in whole or in part, and at any time thereafter as requested by the Company, you hereby agree to make adequate provision for (including by means of a "same day sale" pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board to the extent permitted by the Company), any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or an Affiliate, if any, which arise in connection with the exercise of this Option.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) In the event that you fail to make the adequate provisions contemplated by <u>Section 11(a)</u> above, then subject to compliance with any applicable legal conditions or restrictions, the Company shall have the option in its discretion (but not the obligation) to withhold from fully vested Common Stock otherwise issuable to you upon the exercise of this Option a number of whole shares of Common Stock having a Fair Market Value, determined by the Company as of the date of exercise, not in excess of the amount of tax required to be withheld by law (or such lower amount as may be necessary to avoid classification of this Option as a liability for financial accounting purposes).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The Company assumes no responsibility for individual income taxes, penalties or interest related to grant or exercise of any option. Neither the Company nor any affiliate makes any representation or undertaking regarding the treatment of any tax withholding in connection with the grant or exercise of any option. You should consult with your personal tax advisor regarding the tax ramifications, if any, which result from receipt of this Option, the subsequent issuance, if any, of Common Stock on exercise of this Option, and subsequent disposition of any such Common Stock. You acknowledge that the Company may be required to withhold federal, state and/or local taxes in connection with the exercise of this Option. You may not exercise this Option unless the tax withholding obligations of the Company and/or any Affiliate are satisfied. Accordingly, you may not be able to exercise this Option when desired even though this Option is vested, and the Company will have no obligation to issue a certificate for such Common Stock or release such Common Stock from any escrow provided for herein, if applicable, unless such obligations are satisfied.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**12. <u>Section 409A; Tax Consequences</u>.** It is the Company's intent that this Option be exempt from Section 409A of the Internal Revenue Code to the extent applicable, and that this Agreement be administered accordingly. You hereby agree that the Company does not have a duty to design or administer the Plan or its other compensation programs in a manner that minimizes your tax liabilities. You will not make any claim against the Company, or any of its officers, directors, employees or Affiliates related to tax liabilities arising from this Option or your other compensation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**13. <u>Notices</u>.** Any notices provided for in this Option or the Plan will be given in writing and will be deemed effectively given upon receipt. The Company may, in its sole discretion, decide to deliver any documents related to participation in the Plan and this Option by electronic means or to request your consent to participate in the Plan by electronic means. By accepting this Option, you consent to receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**14. <u>Agreement Summaries</u>.** In the event that the Company provides you (or anyone acting on your behalf) with summary or other information concerning, including or otherwise relating to your rights or benefits under this Agreement (including, without limitation, this Option and any exercise thereof), such summary or other information shall in all cases be qualified in its entirety by **<u>Exhibit A</u>**, **<u>Exhibit B</u>**, the Grant Notice, this Agreement, the Plan and the Notice of Exercise and, unless it explicitly states otherwise and is signed by an officer of the Company, shall not constitute an amendment or other modification hereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**15. <u>Clawback</u>.** Notwithstanding anything to the contrary in this Agreement, the Common Stock issued in connection with this Agreement, any restricted stock unit agreement or any other stock option agreement, and all amounts that may be received by you in connection with any disposition of any such Common Stock shall be subject to applicable recoupment, "clawback" and similar provisions under Applicable Law, as well as any recoupment, "clawback" and similar policies of the Company that may be adopted at any time and from time to time for any reason, including in order to comply with the Dodd-Frank Wall Street Reform and Consumer Protection Act or other Applicable Law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**16. <u>Acknowledgements</u>.** You understand, acknowledge, agree and hereby stipulate that: (a) you are executing this Agreement voluntarily and without any duress or undue influence by the Company or anyone else; (b) this Option is intended to be consideration in exchange for the promises and covenants set forth in this Agreement; (c) you have carefully read, considered and understand all of the provisions of this Agreement and the Company's policies reflected in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged; (d) you have asked any questions needed for you to understand the terms, consequences and binding effect of this Agreement and you fully understand them; (e) you were provided an opportunity to seek the advice of an attorney and/or a tax professional of your choice before accepting this Option and (f) the obligations and restrictions set forth in this Agreement are fair and reasonable. In addition, you understand, acknowledge, agree and hereby stipulate that (1) you explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Agreement and any other award materials by and among the Company and its Affiliates for the purpose of implementing, administering and managing your participation in the Plan; (2) you understand that the Company may hold certain personal information about you, including, but not limited to, the your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares or directorships held in the Company, details of all awards, or any other entitlement to shares awarded, canceled, exercised, vested, unvested or outstanding in your favor ("***Data***"), for the purpose of implementing, administering and managing the Plan; (3) you understand that Data will be transferred to such stock plan service provider as may be selected by the Company, presently or in the future, which may be assisting the Company with the implementation, administration and management of the Plan; (4) you authorize the Company, the stock plan service provider as may be selected by the Company, and any other possible recipients which may assist the Company, presently or in the future, with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan; (5) you understand that you are providing the consents herein on a purely voluntary basis.; (6) if you do not consent, or if you later seeks to revoke your consent, or instruct the Company to cease the processing of the Data, your employment status will not be adversely affected and the only adverse consequence of refusing or withdrawing your consent or instructing the Company to cease processing, is that the Company would not be able to grant you options or any other equity awards or administer or maintain such awards; and (7) you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan.

**ATTACHMENT II**

**GLUCOTRACK INC. 2024 EQUITY INCENTIVE PLAN**

**(attached)**

**ATTACHMENT III**

**FORM OF NOTICE OF EXERCISE**

**GLUCOTRACK INC.**

**2024 EQUITY INCENTIVE PLAN**

**<u>NOTICE OF EXERCISE</u>**

Glucotrack Inc.

[Address]

[Address]

Name of Optionholder:  

Date of Exercise: __________ _____, 20__

This constitutes notice under my stock option that I elect to purchase the number of shares of Common Stock for the price set forth below.

---

| | |
|:---|:---|
| Type of Option (check one): | ☐ Incentive Stock Option |
|  | ☐ Non-Qualified Stock Option |
| Stock Option Date of Grant: |  |
| Number of shares of Common Stock as to which this Option is exercised: |  |
| Common Stock to be issued in name of: |  |
| Total exercise price: |  |
| Cash payment delivered herewith: |  |
| Non-cash payment delivered herewith: |  |

---

By this exercise, I agree (i) to provide such additional documents as you may require in connection with the Glucotrack Inc. 2024 Equity Incentive Plan (the "***Plan***"), (ii) to provide for the payment by me to you (in the manner designated by you) of your withholding obligation, if any, relating to the exercise of this Option, and (iii) if this exercise relates to an Incentive Stock Option, to notify you in writing within fifteen (15) days after the date of any disposition of any Common Stock issued upon exercise of this Option that occurs within two (2) years after the Date of Grant of this Option or within one (1) year after such Common Stock is issued upon exercise of this Option.

---

| |
|:---|
| Very truly yours. |
| Signature |
| Address: |

---

## Ex-Filing

?xml version='1.0' encoding='ASCII'?

**Exhibit 107**

**CALCULATION OF FILING FEE TABLE**

**Form S-8**

(Form Type)

**Glucotrack, Inc.**

(Exact Name of Registrant as Specified in its Charter)

**Table 1 - Newly Registered Securities**

Fees Previously Paid

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| Security Type | Security <br> Class <br>Title | Fee <br> Calculation <br>Rule | Amount <br>Registered |  | Proposed <br>Maximum <br>Offering <br>Price <br>Per Share |  | Maximum <br>Aggregate <br>Offering <br>Price | Fee Rate | Amount of <br>Registration <br>Fee |
| Equity | Common Stock, par value $0.001 per share | Other(1) | 124555 | (2) | $4.32 | (1) | $538077.60 | 0.00015310 | $82.38 |
| Total Offering Amounts | Total Offering Amounts | Total Offering Amounts | Total Offering Amounts |  |  |  | $538077.60 |  | $82.38 |
| Total Fee Offsets | Total Fee Offsets | Total Fee Offsets | Total Fee Offsets |  |  |  |  |  | $– |
| Net Fee Due | Net Fee Due | Net Fee Due | Net Fee Due |  |  |  |  |  | $82.38 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Estimated
 in accordance with Rule 457(c) and Rule 457(h) under the Securities Act, based on the average of the high and low prices of the Registrant's
 Class A common stock on the Nasdaq Capital Market on August 29, 2025, which date is within five business days prior to filing
 this registration statement.

(2) Represents
 shares of common stock that are authorized for issuance under the Glucotrack, Inc. 2024 Equity Incentive Plan, as amended (the "Plan"),
 pursuant to the amendment to the Plan adopted by the Registrant's stockholders on May 22, 2025, which increased the number
 of shares authorized under the Plan to 125,000 shares (as reduced in connection with the Registrant's one-for-sixty
 (1:60) reverse stock split, effective June 13, 2025). 445 shares of common stock issuable under the Plan (which reflects the
 Registrant's one-for-twenty (1:20) reverse stock split, effective February 3, 2025 and the Registrant's one-for-sixty
 (1:60) reverse stock split, effective June 13, 2025) have been previously registered on the Registrant's registration statement
 on Form S-8 filed with the Commission on August 19, 2024 (File No. 333-281627). Pursuant to Rule 416(a) of the Securities
 Act of 1933, as amended (the "Securities Act"), this registration statement also includes an indeterminate number of
 additional shares of common stock that may become issuable pursuant to the anti-dilution provisions of the Plan.

N/A